Importantly, the percentage of both CD4+ (13.8 to 23.0%; Supplementary Fig. 11c) and CD8+ T (9.7 to 17.8%; Supplementary Fig. 11d) cells in the blood doubled after acGM-1.8 treatment, providing further evidence of the restoration of anti-cancer adaptive immunity. The gene discussed is CD4; the disease is cancer.